Congress highlights
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼


Repatha® at ESC 2019

Updated ESC/EAS dyslipidaemia guidelines: Lower is better

ESC Congress 2019 in Paris, France, saw the launch of updated guidelines for the management of dyslipidaemias featuring lower LDL-C goals across CV risk categories and the endorsement of PCSK9 inhibitors in patients unable to achieve LDL-C targets with maximally tolerated statin and ezetimibe, including patients hospitalised with acute coronary syndromes (ACS).1

EVOPACS study: Early start, early LDL-C reduction with Repatha® in ACS

Results of the EVOPACS study were presented at ESC 2019 and showed that:
  • Repatha® given in the acute phase of ACS delivered a powerful 77% reduction in LDL-C from baseline, when added to a high-intensity statin2
  • By adding Repatha®, 9 out of 10 patients reached the more stringent 2019 ESC/EAS LDL-C target of <55 mg/dl2

€10K raised for the World Heart Federation

At the Amgen booth we raised awareness of The Alarming Truth About Cholesterol with activities including an interactive quiz, a cycling challenge and our atherosclerosis colouring wall.
Amgen made a donation for each activity completed by delegates, raising an impressive €10,000 for the World Heart Federation.

*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Mach F, et al. Eur Heart J. 2020;41:111-88.
  2. Koskinas KC, et al. J Am Coll Cardiol. 2019;74:2452-62.
  3. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.